Pharmacotherapy of depression: Recent developments;Dépression: Le point sur les traitements psychopharmacologiques

Revue Medicale Suisse

Volumn 3, Issue 125, 2007, Pages 2079-2084

  Baumann, Pierre ^a  

^a Département de Psychiatrie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESVENLAFAXINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; OLANZAPINE; QUETIAPINE; VENLAFAXINE;

ARTICLE; DEPRESSION; DRUG INDUSTRY; DRUG MECHANISM; HUMAN; SEROTONINERGIC SYSTEM;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; HUMANS;

EID: 34848859003     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kuhn R. Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G 22355). Schweiz Med Wochenschr 1957;35/36:590-601.
2. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967;113:1237-64.
3. Matussek N. Neurobiologie und Depression. Med Monatsschr 1966;3:109-12.
4. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1:132-6.
5. Schildkraut JJ. The catecholamine hypothesis of affective disorders : A review of supporting evidence. Am J Psychiatry 1965;12:509.
6. Ables AZ, Baughman OL. Antidepressants : Update on new agents and indications. Am Fam Physician 2003; 67:547-54.
7. * Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems : A dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004;7:193-218.
8. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-24.
9. Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 2003;23:182-92.
10. Cookson J, Gilaberte I, Desaiah D, Kajdasz DK. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol 2006;21:267-73.
11. Hirschfeld RMA, Vornik LA. Newer antidepressants : Review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004;65(Suppl. 4):46-52.
12. Anonymous. Duloxetine - Depression and diabetic neuropathy : Too many adverse effects. Prescrire Int 2006;15:168-72.
13. Gysling E. Duloxetin. Pharma-kritik 2006;28:9-11.
14. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-7.
15. * Dando TM, Keating GM. Quetiapine : A review of its use in acute mania and depression associated with bipolar disorder. Drugs 2005;65:2533-51.
16. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression : A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26: 600-9.
17. Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 2007;20:23-9.
18. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20:29-42.
19. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68:677-88.
20. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate : A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65.
21. Hanoun N, Mocaer E, Boyer PA, Hamon M, Lanfumey L. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HTIA receptors in the rat brain. Neuropharmacology 2004; 47:515-26.
22. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states : Focus on novel therapeutic strategies. Therapie 2005; 60:441-60.
23. Wood MD, Thomas DR, Watson JM. Therapeutic potential of serotonin antagonists in depressive disorders. Expert Opin Investig Drugs 2002;11:457-67.
24. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64.
25. Lôo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder : A placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47.
26. Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) 2007;190:575-9.
27. Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006;21(Suppl. 1):S31-5.
28. * Montgomery SA. Major depressive disorders : Clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol 2006; 16(Suppl. 5):S633-8.
29. Rojo JE, Ros S, Aguera L, et al. Combined antidepressants : Clinical experience. Acta Psychiatrica Scandinavica, Supplementum 1936;428:25-31.
30. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64:403-7.
31. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001;34: 119-27.
32. * Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-66.
33. Foley KF, DeSanty KP, Kast RE. Bupropion : Pharmacology and therapeutic applications. Expert Rev Neuroner 2006;6:1249-65.
34. Clayton AH. Extended-release bupropion : An antidepressant with a broad spectrum of therapeutic activity ? Expert Opin Pharmacother 2007;8:457-66.
35. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42.
36. * Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-52.
37. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl : From bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005;7:106-13.
38. Rosack J. Companies desperately seek antidepressant breakthrough. Psychiatr News 2006;41:22-37.
39. Paul IA, Skolnick P. Glutamate and depression : Clinical and preclinical studies. Ann N Y Acad Sci 2003;1003:250-72.
40. Millan MJ. The role of monoamines in the actions of established and «novel» antidepressant agents : A critical review. Eur J Pharmacol 2004;500:371-84.
41. Stahl SM. Overview of trends in modern psychopharmacology. CNS Spear 2007;12:103-5.
42. * Millan MJ. Multi-target strategies for the improved treatment of depressive states : Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
43. * Baghai TC, Volz HP, Moller HJ. Drug treatment of depression in the 2000s : An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006;7:198-222.
44. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-5.
45. Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry 1998;155:457-69.
46. Kandel ER. Biology and the future of psychoanalysis : A new intellectual framework for psychiatry revisited. Am J Psychiatry 1999;156:505-24.
47. Goldapple K, Segal Z, Garson C, et al. Modulation of cortical-limbic pathways in major depression - treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004;61:34-41.